Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Atherosclerosis | 10 | 2023 | 3418 | 1.540 |
Why?
|
Lipoproteins | 3 | 2022 | 870 | 1.140 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3249 | 0.940 |
Why?
|
Cardiovascular Diseases | 12 | 2023 | 15647 | 0.840 |
Why?
|
Hypertriglyceridemia | 2 | 2023 | 292 | 0.810 |
Why?
|
Triglycerides | 3 | 2023 | 2441 | 0.630 |
Why?
|
Cardiology | 4 | 2022 | 1696 | 0.620 |
Why?
|
Secondary Prevention | 2 | 2021 | 1470 | 0.580 |
Why?
|
Primary Prevention | 2 | 2021 | 1187 | 0.530 |
Why?
|
Renin-Angiotensin System | 1 | 2021 | 736 | 0.520 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1121 | 0.440 |
Why?
|
Coronary Artery Disease | 2 | 2024 | 6544 | 0.410 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2021 | 1735 | 0.390 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 3930 | 0.380 |
Why?
|
Stroke | 3 | 2024 | 9748 | 0.370 |
Why?
|
Lipid Regulating Agents | 2 | 2020 | 21 | 0.360 |
Why?
|
Population Surveillance | 1 | 2021 | 2596 | 0.350 |
Why?
|
Apolipoprotein C-III | 2 | 2022 | 209 | 0.330 |
Why?
|
Heart Failure | 3 | 2023 | 11837 | 0.330 |
Why?
|
Eicosapentaenoic Acid | 3 | 2023 | 565 | 0.320 |
Why?
|
Veterans | 1 | 2023 | 2667 | 0.320 |
Why?
|
Coronary Vessels | 1 | 2020 | 3094 | 0.320 |
Why?
|
Blood Pressure | 2 | 2022 | 8532 | 0.310 |
Why?
|
Brain Ischemia | 1 | 2022 | 3002 | 0.310 |
Why?
|
Heart Ventricles | 1 | 2021 | 3833 | 0.310 |
Why?
|
American Heart Association | 3 | 2022 | 1045 | 0.300 |
Why?
|
Peptide Fragments | 1 | 2021 | 5126 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 12235 | 0.290 |
Why?
|
Calcium | 1 | 2020 | 5770 | 0.280 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2021 | 2306 | 0.270 |
Why?
|
Mississippi | 1 | 2024 | 93 | 0.230 |
Why?
|
Risk Assessment | 4 | 2024 | 24276 | 0.230 |
Why?
|
Fibric Acids | 1 | 2023 | 27 | 0.210 |
Why?
|
Hypertension | 2 | 2022 | 8616 | 0.210 |
Why?
|
Risk Factors | 9 | 2024 | 74857 | 0.190 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 462 | 0.190 |
Why?
|
Lipoprotein-X | 1 | 2020 | 5 | 0.180 |
Why?
|
Inflammation | 1 | 2020 | 10860 | 0.180 |
Why?
|
Echocardiography, Stress | 1 | 2020 | 137 | 0.160 |
Why?
|
Humans | 25 | 2024 | 766117 | 0.140 |
Why?
|
Protein Precursors | 1 | 2021 | 1133 | 0.130 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2021 | 396 | 0.130 |
Why?
|
United States | 7 | 2024 | 72920 | 0.130 |
Why?
|
Electric Countershock | 1 | 2019 | 536 | 0.130 |
Why?
|
Reminder Systems | 1 | 2019 | 388 | 0.130 |
Why?
|
Incidence | 3 | 2024 | 21513 | 0.130 |
Why?
|
Cardiovascular System | 1 | 2022 | 838 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 848 | 0.110 |
Why?
|
Prognosis | 3 | 2024 | 29912 | 0.110 |
Why?
|
Dyslipidemias | 1 | 2020 | 871 | 0.100 |
Why?
|
Antihypertensive Agents | 1 | 2022 | 2028 | 0.100 |
Why?
|
Middle Aged | 7 | 2024 | 223083 | 0.100 |
Why?
|
RNA Interference | 1 | 2020 | 2828 | 0.090 |
Why?
|
Massachusetts | 1 | 2024 | 8882 | 0.090 |
Why?
|
Ischemia | 1 | 2020 | 1904 | 0.090 |
Why?
|
Time Factors | 2 | 2024 | 40108 | 0.090 |
Why?
|
Aged | 6 | 2024 | 171219 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2019 | 1568 | 0.090 |
Why?
|
Monocytes | 1 | 2020 | 2591 | 0.090 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59515 | 0.090 |
Why?
|
Women's Health | 1 | 2020 | 2081 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1878 | 0.080 |
Why?
|
Defibrillators, Implantable | 1 | 2019 | 1497 | 0.080 |
Why?
|
Female | 11 | 2024 | 396233 | 0.080 |
Why?
|
Male | 9 | 2024 | 363935 | 0.080 |
Why?
|
Prospective Studies | 3 | 2024 | 54812 | 0.080 |
Why?
|
Stroke Volume | 2 | 2023 | 5595 | 0.080 |
Why?
|
Coronary Disease | 1 | 2023 | 5919 | 0.080 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2019 | 2136 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2019 | 2068 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2021 | 2431 | 0.070 |
Why?
|
Registries | 1 | 2022 | 8347 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2023 | 10380 | 0.060 |
Why?
|
Prevalence | 1 | 2022 | 15827 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5185 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26290 | 0.060 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16716 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4863 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 16040 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8725 | 0.040 |
Why?
|
Telecommunications | 1 | 2020 | 79 | 0.040 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2021 | 212 | 0.040 |
Why?
|
Adult | 6 | 2024 | 223139 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39243 | 0.040 |
Why?
|
Pennsylvania | 1 | 2019 | 615 | 0.040 |
Why?
|
Oligonucleotides | 1 | 2020 | 561 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 59868 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2021 | 682 | 0.030 |
Why?
|
Glucosides | 1 | 2020 | 532 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2020 | 811 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 943 | 0.030 |
Why?
|
Europe | 1 | 2020 | 3430 | 0.030 |
Why?
|
HIV Infections | 1 | 2020 | 17535 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2020 | 1148 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3202 | 0.030 |
Why?
|
Cause of Death | 1 | 2019 | 3715 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3955 | 0.020 |
Why?
|
Genetic Testing | 1 | 2021 | 3594 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10579 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3617 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12426 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 8038 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18386 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 81565 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41684 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88819 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2019 | 65219 | 0.010 |
Why?
|
Concepts
(109)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(6)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_